Concord Drugs Intrinsic Value
Concord Drugs (CONCORD) median intrinsic value is ₹41.36 from 9 valuation models (range ₹23–₹151), vs current price ₹75.30 — -45.1% downside (Trading Above Calculated Value), margin of safety -82.1%. Check Concord Drugs market worth to track the company's total market size over time.
CONCORD Valuation Methods Summary — DCF, Graham Number & P/E
Concord Drugs intrinsic value across 9 models vs current price ₹75.30 — upside/downside and value range per method. For current market price and key ratios, visit Concord Drugs share price today.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹41.36 | ₹33.09 - ₹49.63 | -45.1% | EPS: ₹1.88, Sector P/E: 22x |
| Book Value Method | asset | ₹75.38 | ₹67.84 - ₹82.92 | +0.1% | Book Value/Share: ₹37.69, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹150.60 | ₹135.54 - ₹165.66 | +100.0% | Revenue/Share: ₹116.92, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹61.54 | ₹55.39 - ₹67.69 | -18.3% | EBITDA: ₹8.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹41.79 | ₹33.43 - ₹50.15 | -44.5% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹22.59 | ₹20.33 - ₹24.85 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹29.05 | ₹26.14 - ₹31.96 | -61.4% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹37.65 | ₹33.88 - ₹41.41 | -50.0% | ROE: 8.2%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹39.93 | ₹35.94 - ₹43.92 | -47.0% | EPS: ₹1.88, BVPS: ₹37.69 |
CONCORD Intrinsic Value vs Market Price — All Valuation Models
Concord Drugs fair value range ₹23–₹151 vs current market price ₹75.30 across 9 valuation models. See CONCORD book value to compare market price against book value per share.
CONCORD Intrinsic Value Analysis — Undervalued or Overvalued?
Concord Drugs median intrinsic value ₹41.36, current price ₹75.30 — Trading Above Calculated Value by 45.1%, margin of safety -82.1%.
What is the intrinsic value of CONCORD?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Concord Drugs (CONCORD) is ₹41.36 (median value). With the current market price of ₹75.30, this represents a -45.1% variance from our estimated fair value.
The valuation range spans from ₹22.59 to ₹150.60, indicating ₹22.59 - ₹150.60.
Is CONCORD undervalued or overvalued?
Based on our multi-method analysis, Concord Drugs (CONCORD) appears to be trading above calculated value by approximately 45.1%.
CONCORD Financial Health — Key Ratios vs Industry Benchmarks
Concord Drugs financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 10.60 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 8.2% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 4.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 2.03x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
CONCORD Cash Flow Quality — Operating & Free Cash Flow
Concord Drugs operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹4 Cr | ₹3 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹2 Cr | ₹1 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹1 Cr | ₹0 Cr | Positive Operating Cash Flow | 6/10 |